414 results on '"Bubela, Tania"'
Search Results
2. “I Just Assumed This Was Already Being Done”: Canadian Patient Preferences for Enhanced Data Sharing for Precision Oncology
3. Asynchronous online focus groups for research with people living with amyotrophic lateral sclerosis and family caregivers: usefulness, acceptability and lessons learned
4. ISSCR Guidelines for Stem Cell Research and Clinical Translation: The 2021 update.
5. Do-It-Yourself and Commercial Automated Insulin Delivery Systems in Type 1 Diabetes: An Uncertain Area for Canadian Health-care Providers
6. “I have such a hard time hitting myself, I thought it’d be easier”: perspectives of hospitalized patients on injecting drugs into vascular access devices
7. Covid-19 threat and coping: application of protection motivation theory to the pandemic experiences of people affected by amyotrophic lateral sclerosis
8. A perspective on life-cycle health technology assessment and real-world evidence for precision oncology in Canada
9. Public Engagement
10. Governance of a global genetic resource commons for non-commercial research : a case-study of the DNA barcode commons
11. The Impact of Heterogeneity in a Global Knowledge Commons : Implications for Governance of the DNA Barcode Commons
12. Canadian newspaper coverage on harm reduction featuring bereaved mothers: A mixed methods analysis
13. Use and misuse of research: Canada’s response to covid-19 and its health inequalities
14. What do people affected by amyotrophic lateral sclerosis want from health communications? Evidence from the ALS Talk Project
15. Non-invasive Prenatal Testing and the Unveiling of an Impaired Translation Process
16. Application of protection motivation theory to clinical trial enrolment for pediatric chronic conditions
17. Policies and Practices to Enhance Multi-sectorial Collaborations and Commercialization of Regenerative Medicine
18. Circumpolar stakeholder perspectives on Geographic Information Systems for communicating the health impacts of development
19. Can Managed Access Agreements Mitigate Evidentiary, Economic and Ethical Issues with Access to Expensive Drugs for Rare Diseases in the Canadian Context?
20. Lessons from Canada’s notice of compliance with conditions policy for the life-cycle regulation of drugs
21. Communicating the Promise for Ocular Gene Therapies: Challenges and Recommendations
22. Amyotrophic lateral sclerosis (ALS) health charities are central to ALS care: perspectives of Canadians affected by ALS
23. Governance of Biomedical Research Commons to Advance Clinical Translation: Lessons from the Mouse Model Community
24. Contributors
25. Legal Issues in Public Health
26. DNA barcoding in the media: does coverage of cool science reflect its social context?
27. Identifying and understanding factors that affect the translation of therapies from the laboratory to patients: a study protocol - Extended Data
28. Public Biological Databases and the Sui GenerisDatabase Right
29. Stepping Into and Out of the Void: Funding Dynamics of Human Embryonic Stem Cell Research in California, Sweden, and South Korea
30. Managing intellectual property to promote pre-competitive research : the mouse as a model for constructing a robust research commons.
31. 'If they tell me to get it, I'll get it. if they don't....': immunization decision-making processes of immigrant mothers
32. Amyotrophic lateral sclerosis (ALS) health charities are central to ALS care: perspectives of Canadians affected by ALS.
33. Molecular Typing Technology: a Legal Perspective
34. CAPTURE ALS: the comprehensive analysis platform to understand, remedy and eliminate ALS
35. The Importance of and Challenges with Adopting Life-Cycle Regulation and Reimbursement in Canada
36. Conditional Drug Approval as a Path to Market for Oncology Drugs in Canada: Challenges and Recommendations for Assessing Eligibility and Regulatory Responsiveness
37. Legal and Regulatory Enablers and Barriers to Conditional Regulatory and Reimbursement Alternatives in Canadian Health Systems
38. CAPTURE ALS: the comprehensive analysis platform to understand, remedy and eliminate ALS.
39. Should Canada adopt managed access agreements in Canada for expensive drugs?
40. Drugs: Regulate ‘home-brew’ opiates
41. Communication About End of Life for Patients Living With Amyotrophic Lateral Sclerosis: A Scoping Review of the Empirical Evidence
42. ISSCR Guidelines for Stem Cell Research and Clinical Translation:The 2021 update
43. The Stem Cell Research Environment: A Patchwork of Patchworks
44. The global landscape of stem cell clinical trials
45. The Comprehensive Analysis Platform To Understand, Remedy, and Eliminate ALS (CAPTURE ALS) (1787)
46. Nutrigenomics, mass media and commercialization pressures.
47. Policies and Practices to Enhance Multi-sectorial Collaborations and Commercialization of Regenerative Medicine
48. Trends in evidence based medicine for herbal remedies and media coverage.
49. Let’s do better: public representations of COVID-19 science
50. Introduction: Indigenous Rights and Traditional Knowledge
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.